Biochemical and pathological characterization of Lrrk2

Annals of Neurology

Volumn 59, Issue 2, 2006, Pages 315-322

  Giasson, Benoit I ^a,c   Covy, Jason P ^a   Bonini, Nancy M ^a   Hurtig, Howard I ^a   Farrer, Matthew J ^b   Trojanowski, John Q ^a   Van Deerlin, Vivianna M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN;

ALZHEIMER DISEASE; ANTIBODY SPECIFICITY; ARTICLE; AUTOPSY; CHEMICAL ANALYSIS; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEWY BODY; LRRK2 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; BRAIN; CELL LINE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; MOLECULAR WEIGHT; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SERINE; TIME FACTORS; TRANSFECTION;

EID: 32044432395     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20791     Document Type: Article

References (30)

1. Simuni T, Hurtig HI. Parkinson's disease: the clinical picture. In: Clark CM, Trojanoswki JQ, eds. Neurodegenerative dementias. New York: McGraw-Hill, 2000:193-203.
2. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
3. Cronford ME, Chang L, Miller, BL. The neuropathology of parkinsonism: an overview. Brain Cogn 1995;28:321-341.
4. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
5. Forman MS, Lee VM-Y, Trojanowski JQ. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron. 2005;47:479-482.
6. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
7. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
8. Ross OA, Farrer MJ. Pathophysiology, pleotrophy and paradigm shifts: genetic lessons from Parkinson's disease. Biochem Soc Trans 2005;33:586-590.
9. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567
10. Giasson BI, Lee VM-Y. Parkin and the molecular pathways of Parkinson's disease. Neuron 2001;31:885-888.
11. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
12. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
13. Farrer M, Stone J, Mata IF, et al. LRRK2 mutations in Parkinson disease. Neurology 2005;65:738-740.
14. Zabetian CP, Samii A, Mosley AD, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 2005;65:741-744.
15. Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease. Neurology 2005;65:696-700.
16. Deng H, Le W, Guo Y, et al. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005;57:933-934.
17. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-416.
18. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365:412-415.
19. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
20. Hernandez D, Paisan RC, Crawley A, et al. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 2005;389:137-139.
21. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-412.
22. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-1622.
23. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005;57:918-921.
24. Hasegawa K, Kowa H. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Eur Neurol 1997;38(suppl 1):39-43.
25. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884.
26. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to oxidized α-synuclein reveal abundant neuritic pathology in Lewy body disease. Ann Neurol 2002;52:205-210.
27. Duda JE, Giasson BI, Gur TL, et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000;59:830-841.
28. Toft M, Sando SB, Melquist S, et al. LRRK2 mutations are not common in Alzheimer's disease. Mech Ageing Dev 2005;126:1201-1205.
29. Hernandez DG, Paisan-Ruiz C, McInerney-Leo A, et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005;57:453-456.
30. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.